Memphasys Limited (FRA:IG7)

Market Cap	11.11M +85.7%
Revenue (ttm)	294.15K +237.8%
Net Income	-2.81M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	2,171
Open	0.0030
Previous Close	0.0030
Day's Range	0.0030 - 0.0030
52-Week Range	0.0010 - 0.0055
Beta	n/a
RSI	49.52
Earnings Date	Nov 27, 2025

About Memphasys

Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid in vitro antioxidant assessment; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2006
• Employees: 24
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IG7

Financial Performance

In fiscal year 2025, Memphasys's revenue was 526,921, an increase of 237.77% compared to the previous year's 156,000. Losses were -5.04 million, -6.19% less than in 2024.

Financial numbers in AUD